期刊文献+

乳腺癌核芯针穿刺印片与组织学诊断的比较研究 被引量:5

Comparison of touch imprint cytology of core needle biopsy and section histopathology in breast cancer diagnosis
原文传递
导出
摘要 目的 探讨印片细胞学(TIC)与组织病理诊断以及印片免疫细胞化学与免疫组织化学检测结果的一致性,评价在乳腺癌新辅助化疗前TIC诊断的临床应用价值.方法 收集行核芯针穿刺组织TIC诊断的乳腺肿物患者289例,其中287例有核芯针活检(CNB)病理结果对照,190例有术后病理结果对照.289例中,64例行印片的雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)免疫细胞化学检测,其中52例有CNB免疫组织化学检测结果,43例有术后病理免疫组织化学检测结果.结果 TIC诊断良性22例,恶性263例,不满意标本4例.假阴性率和不满意率均为1.4%,假阳性率为0.35%.与术后病理结果比较,TIC和CNB诊断乳腺癌的敏感性分别为96.2%和95.0%(P=0.601),特异性分别为87.5%和100%(P=0.471),准确率分别为95.8%和95.3%(P=0.804),差异均无统计学意义.ER、PR和HER-2印片免疫细胞化学检测结果与CNB的免疫组织化学检测结果的符合率分别为86.5%、75.0%和78.8%,与术后病理免疫组织化学检测结果的符合率分别为88.4%、74.4%和75.6%,CNB与术后病理免疫组织化学检测结果的符合率分别为83.7%、74.4%和76.5%,三者差异无统计学意义(P>0.05).结论 TIC诊断乳腺癌的敏感性、特异性和准确率较高,与CNB组织病理诊断无明显差异,可以辅助CNB为乳腺肿物患者提供快速的细胞学诊断.印片免疫细胞化学方法可以辅助CNB作为新辅助化疗前检测乳腺癌患者受体水平的手段之一. Objective To evaluate the sensitivity, specificity of touch imprint cytology(TIC), and to compare its conformity rate with histopathology, to observe the consistence of immunocytochemistry(ICC)with immunohistochemistry(IHC), and to assess the diagnostic value of TIC prior to neoadjuvant chemotherapy for breast cancer. Methods 289 cases of TIC and 287 cases with core needle biopsy(CNB)histopathology accumulated from October 2005 to October 2008 in our hospital were included in this study.One hundred ninety cases TIC results were compared with that of final histopathology. 64 cases were tested for ER, PR, HER-2 by immunocytochemistry. Results Twenty-four benign cases and 265 malignant cases were diagnosed. 4 specimens were unsatisfactory. False negative rate and unsatisfactory rate were 1. 4%,both, and false positive rate was 0.35%. The accuracy rate of TIC and CNB was 95.8% and 95.3%,respectively(P =0.804). The sensitivity of TIC and CNB was 96.2% and 95.0%(P =0.601), specificity 87.5% and 100%(P =0.471)were found, when compared with the results of routine histopathology. 52cases had a control with IHC of CNB in 64 ICC, and 43 cases had a final histopathology IHC. The ICC conformity rate of ER, PR, HER-2 with IHC of CNB was 86.5%, 75.0%, 78.8%, and that with IHC of final histopathology was 88.4%, 74.4%, 75.6%, respectively. The conformity rate of IHC between CNB and final histopathology was 83.7%, 74.4%, 76.5%, respectively. There was no significant statistical difference between them. Conclusion Compared with routine CNB histopathology, TIC has a high accuracy and sensitivity, and can provide a rapid and reliable cytological diagnosis to complement CNB for breast lesions. The conformity rates are high in ER, PR, HER-2 expression between ICC and IHC. ICC of TIC can be used to determine the estrogen and progesterone receptor levels in breast cancer before neoadjuvant chemotherapy.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2010年第12期921-926,共6页 Chinese Journal of Oncology
基金 北京市科技计划课题(D0905001040131)
关键词 乳腺肿瘤 印片细胞学 组织学技术 核芯针穿刺术 免疫细胞化学 免疫组织化学 受体 雌激素 受体 孕激素 人表皮生氏因子受体2 Breast neoplasms Touch imprint cytology Histopathological techniques Core needle punctures Immunocytochemistry Immunohistochemstry Receptors, estrogen Receptors,progesterone HER-2
  • 相关文献

参考文献17

  • 1郑闪,张柏林,邹霜梅,林冬梅,薛丽燕,罗巍,吕宁.核芯针活检在乳腺癌新辅助化疗前的组织学诊断评价[J].中华病理学杂志,2008,37(2):99-102. 被引量:4
  • 2Klevesath MB,Godwin RJ,Bannon R,et al.Touch imprint cytology of core needle biopsy specimens:a useful method for immediate reporting of symptomatic breast lesions.Eur J Surg Oncol,2005,31:490-494.
  • 3Oikonomou V,Fotou M,Zagouri F,et al.Imprint cytology of vacuumassisted breast biopsy specimens:a rapid diagnostic tool in nonpalpable solid lesions.Cytopathology,2008,19:311-315.
  • 4Douglas-Jones AC,Collett N,Morgan JM,et al.Comparison of core oestrogen receptor(ER)assay with excised tumour:intratumoral distribution of ER in breast carcinoma.J Clin Pathol,2001,54:951-955.
  • 5Masood S,Fryberg ER,Mclellan GL,et al.Applicatioo of estrogen receptor immunocytochemical assay to aspirates from mammographicallyguided fine needle biopsy of nonpalpable breast lesions.South Med J,1991,84:857-861.
  • 6Sneige N,Tulbah A.Accuracy of cytologic diagnoses made from touch imprints of image-guided needle biopsy specimens of nonpalpable breast abnormalities.Diagn Cytopathol,2000,23:29-34.
  • 7Qureshi NA,Beresford A,Sami S,et al.Imprint cytology of needle core-biopsy specimens of breast lesions:is it a useful adjunt to rapid assessment breast clinics? Breast,2007,16:81-85.
  • 8Berner A,Davidson B,Sigstad E,et al.Fine-needle aspiration cytology vs.core biopsy in the diagnosis of breast lesions.Diagn Cytopathol,2003,29:344-348.
  • 9Newman MR,Frost FA,Sterrett GF,et al.Diagnosis of breast microcalcifications:a comparison of stereotactic FNA and core imprint cytology as adjuncts to core biopsy.Pathology,2001,33:449-453.
  • 10Green RS,Mathew S.The contribution of cytologic imprints of stereotactically guided core needle biopsies of the breast in the management of patients with mammographic abnormalities.Breast J,2001,7:214-218.

二级参考文献8

  • 1Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer——recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer, 2004,11(2):139-147.
  • 2Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Insfitut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol, 1999, 10(1):47-52.
  • 3Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for rnastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol, 1998,9(11):1179-1184.
  • 4Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16(8):2672-2685.
  • 5Leifland K, Lagerstedt U, Svane G. Comparison of stereotactic fine needle aspiration cytology and core needle biopsy in 522 non-palpable breast lesions. Acta Radiol, 2003,44(4):387-391.
  • 6Kurosumi M. Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer, 2006, 13(3):254-259.
  • 7Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma//Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs 1st. Lyon: IARC Press, 2003:13-59.
  • 8Yaziji H, Gown AM, Sneiqe N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol, 2000,7(2):100-109.

共引文献3

同被引文献34

  • 1Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu and fluorescence in situ hybridization results in breast cancer[ J ]. Am J Clin Pathol, 2011, 136 (5) :754-761.
  • 2Coutuier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 ( HER-2/ neu) gene status in breast carcinoma[J]. Mod Pathol, 2000, 13 (11) :1238-1243.
  • 3Beatty BG, Bryant R, Wang W, et al, HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis [ J ]. Am J Clin Pathol, 2004, 122(2) :246-255.
  • 4Bofin AM, Ytterhus B, Martin C, et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma[J]. Am J Clin Pathol, 2004, 122(1) :110-119.
  • 5Lee JW, Noh WC, Kim MS, et al. Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients [ J ]. Korean J lab Med, 2008, 28 (5) :392- 399.
  • 6Gu M, Ghafari S, Zhao M, et al. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens [ J ]. Acta Cytol, 2005, 49 (5) :471-476.
  • 7Kapila K, A1-Awadhi S, Francis I. Her-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: a pilot study comparing FISH, CISH and immunocytochemistry [ J ]. J Cytol, 2011,28(2) :54-56.
  • 8Kuo SJ, Wang BB, Chang CS, et al. Cow.son of itochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwan Residents breast cancer patients [ J ]. Taiwan J Obstet Gyneeol, 2007, 46(2):146-151.
  • 9Murthy SS, Sandhya DG, Ahmed F, et al. Assessment of HER2/ Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center [J]. Indian J Pathol Mierebiol, 2011, 54(3) :532-538.
  • 10Halimi M, A AA, Tabrizi AD, ctal. Expreion d epi&m growth factor ce.or tyrosine kinase family in fine needle aspiration and permanent specimens of invasive lobular and ductal breast cancers [J]. Pak J Biol Sci, 2011, 14(10) :584-589.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部